<code id='625DE06758'></code><style id='625DE06758'></style>
    • <acronym id='625DE06758'></acronym>
      <center id='625DE06758'><center id='625DE06758'><tfoot id='625DE06758'></tfoot></center><abbr id='625DE06758'><dir id='625DE06758'><tfoot id='625DE06758'></tfoot><noframes id='625DE06758'>

    • <optgroup id='625DE06758'><strike id='625DE06758'><sup id='625DE06758'></sup></strike><code id='625DE06758'></code></optgroup>
        1. <b id='625DE06758'><label id='625DE06758'><select id='625DE06758'><dt id='625DE06758'><span id='625DE06758'></span></dt></select></label></b><u id='625DE06758'></u>
          <i id='625DE06758'><strike id='625DE06758'><tt id='625DE06758'><pre id='625DE06758'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:8
          he exterior of the U.S. Capitol building is seen at sunrise
          Sarah Silbiger/Getty Images

          WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

          The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

          advertisement

          • One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
          • Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
          • A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

          The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more
          CEOs share strategies for surviving biotech slump
          CEOs share strategies for surviving biotech slump

          JonathanWosenforSTATCARLSBAD,Calif.—BiotechCEOsleadingcellandgenetherapycompaniesspokefranklyataconf

          read more
          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

          1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

          read more

          STAT Summit: Biotech founders on deal

          Fromleft,EliLilly'sJacobS.VanNaarden,Avenzo'sAthenaCountouriotis,andBiohaven'sVladCoriconstageatthe2